ECSP22084264A - Compuestos de Azalactama como inhibidores de HPK1 - Google Patents

Compuestos de Azalactama como inhibidores de HPK1

Info

Publication number
ECSP22084264A
ECSP22084264A ECSENADI202284264A ECDI202284264A ECSP22084264A EC SP22084264 A ECSP22084264 A EC SP22084264A EC SENADI202284264 A ECSENADI202284264 A EC SENADI202284264A EC DI202284264 A ECDI202284264 A EC DI202284264A EC SP22084264 A ECSP22084264 A EC SP22084264A
Authority
EC
Ecuador
Prior art keywords
compounds
azalactam
hpk1 inhibitors
salts
hpk1
Prior art date
Application number
ECSENADI202284264A
Other languages
English (en)
Inventor
Joyann Barber
Mingying He
Ru Zhou
Anne-Marie Dechert Schmitt
Bel Matthew L Del
Rebecca Anne Gallego
Robert Steven Kania
Sajiv Krishnan Nair
Dahui Zhou
Sujin Cho-Schultz
Mehran Jalaie
Michele Ann Mctigue
Jamison Bryce Tuttle
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of ECSP22084264A publication Critical patent/ECSP22084264A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La presente invención se refiere a compuestos de la Fórmula general I I y sales farmacéuticamente aceptables de los mismos, en los que R1, R2, R3a, R3b y R4 son como se definen en el presente documento, a composiciones farmacéuticas que comprenden dichos compuestos y sales, y a métodos de uso de dichos compuestos, sales y composiciones para el tratamiento del crecimiento celular anormal, incluido el cáncer.
ECSENADI202284264A 2020-05-01 2022-10-28 Compuestos de Azalactama como inhibidores de HPK1 ECSP22084264A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202063018689P 2020-05-01 2020-05-01

Publications (1)

Publication Number Publication Date
ECSP22084264A true ECSP22084264A (es) 2022-11-30

Family

ID=75769663

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI202284264A ECSP22084264A (es) 2020-05-01 2022-10-28 Compuestos de Azalactama como inhibidores de HPK1

Country Status (18)

Country Link
US (1) US11684616B2 (es)
EP (1) EP4143186A1 (es)
JP (1) JP7303948B2 (es)
KR (1) KR20230003128A (es)
CN (1) CN115698004A (es)
AR (1) AR121985A1 (es)
AU (1) AU2021265578B2 (es)
CA (1) CA3181415A1 (es)
CL (1) CL2022003007A1 (es)
CO (1) CO2022015448A2 (es)
CR (1) CR20220548A (es)
EC (1) ECSP22084264A (es)
IL (1) IL297838A (es)
MX (1) MX2022013401A (es)
PE (1) PE20230323A1 (es)
TW (1) TWI806043B (es)
UY (1) UY39193A (es)
WO (1) WO2021220185A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102650496B1 (ko) 2018-10-31 2024-03-26 길리애드 사이언시즈, 인코포레이티드 Hpk1 억제제로서의 치환된 6-아자벤즈이미다졸 화합물
CN117105933A (zh) 2018-10-31 2023-11-24 吉利德科学公司 具有hpk1抑制活性的取代的6-氮杂苯并咪唑化合物
WO2020237025A1 (en) 2019-05-23 2020-11-26 Gilead Sciences, Inc. Substituted exo-methylene-oxindoles which are hpk1/map4k1 inhibitors
WO2023057883A1 (en) 2021-10-05 2023-04-13 Pfizer Inc. Crystalline form of azalactam compound
WO2023057882A1 (en) * 2021-10-05 2023-04-13 Pfizer Inc. Combinations of azalactam compounds with a pd-1 axis binding antagonist for the treatment of cancer

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
GB9518953D0 (en) 1995-09-15 1995-11-15 Pfizer Ltd Pharmaceutical formulations
WO2000035296A1 (en) 1996-11-27 2000-06-22 Wm. Wrigley Jr. Company Improved release of medicament active agents from a chewing gum coating
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
WO2008063888A2 (en) 2006-11-22 2008-05-29 Plexxikon, Inc. Compounds modulating c-fms and/or c-kit activity and uses therefor
US10800773B2 (en) 2016-09-12 2020-10-13 Integral Health, Inc. Monocyclic compounds useful as GPR120 modulators
US10787435B2 (en) 2017-01-22 2020-09-29 Fuijan Cosunter Pharmaceutical Co. Ltd. ASK1 inhibitor and preparation method and use thereof
WO2018151830A1 (en) 2017-02-17 2018-08-23 Fronthera U.S. Pharmaceuticals Llc Pyridinyl based apoptosis signal-regulation kinase inhibitors
KR20190126322A (ko) 2017-03-03 2019-11-11 장쑤 한서 파마슈티칼 그룹 캄파니 리미티드 아미드 유도체 억제제 및 그의 제조 방법 및 적용
CN110402248B (zh) * 2017-03-15 2023-01-06 豪夫迈·罗氏有限公司 作为hpk1抑制剂的氮杂吲哚类
JOP20190221A1 (ar) 2017-04-05 2019-09-23 Seal Rock Therapeutics Inc مركبات مثبطات كيناز منظم لإشارات الاستماتة 1 (ask1) واستخداماتها
CN109265443B (zh) * 2017-07-18 2022-11-29 南京圣和药业股份有限公司 作为ask抑制剂的杂环化合物及其应用
WO2019148005A1 (en) 2018-01-26 2019-08-01 Nurix Therapeutics, Inc. Inhibitors of cbl-b and methods of use thereof
US11142525B2 (en) * 2018-11-15 2021-10-12 Pfizer Inc. Azalactam compounds as HPK1 inhibitors
WO2021050964A1 (en) 2019-09-13 2021-03-18 Nimbus Saturn, Inc. Hpk1 antagonists and uses thereof
WO2021224818A1 (en) 2020-05-08 2021-11-11 Pfizer Inc. Isoindolone compounds as hpk1 inhibitors

Also Published As

Publication number Publication date
CO2022015448A2 (es) 2022-11-18
IL297838A (en) 2023-01-01
CA3181415A1 (en) 2021-11-04
AR121985A1 (es) 2022-07-27
MX2022013401A (es) 2022-11-14
US11684616B2 (en) 2023-06-27
CL2022003007A1 (es) 2023-06-16
TW202202496A (zh) 2022-01-16
PE20230323A1 (es) 2023-02-22
EP4143186A1 (en) 2023-03-08
KR20230003128A (ko) 2023-01-05
AU2021265578B2 (en) 2024-03-28
TWI806043B (zh) 2023-06-21
JP7303948B2 (ja) 2023-07-05
CR20220548A (es) 2022-12-12
AU2021265578A1 (en) 2022-11-10
WO2021220185A1 (en) 2021-11-04
UY39193A (es) 2021-11-30
CN115698004A (zh) 2023-02-03
US20220401424A1 (en) 2022-12-22
JP2023515900A (ja) 2023-04-14

Similar Documents

Publication Publication Date Title
CL2022003007A1 (es) Compuestos de azalactama como inhibidores de hpk1
UY38553A (es) Inhibidores de cdk2
CL2021001190A1 (es) Compuestos de azalactam como inhibidores de hpk1
NI201900013A (es) Inhibidor de piridopirimidinona cdk2/4/6
UY38752A (es) Derivados de benzisoxazol sulfonamida
UY37900A (es) Nuevos derivados de rapamicina
UY38196A (es) Inhibidores de cinasa dependientes de ciclina
NI201400102A (es) Derivados macrocíclicos para el tratamiento de enfermedades proliferativas
UY36170A (es) Compuestos de dihidroisoquinolinona sustituida
UY33071A (es) Nuevos compuestos tricíclicos
ECSP14013215A (es) Compuestos novedosos
ECSP22038509A (es) Aminas de heteroaril-bifenilo para el tratamiento de enfermedades pd-l1
ECSP22038478A (es) Heteroaril bifenil amidas para el tratamiento de enfermedades relacionadas con el ligando pd-l1
DOP2023000281A (es) Inhibidores de mutación de her2
CO2021013166A2 (es) Compuestos de hexahidro-1h-pirazino[1,2-a]pirazina para el tratamiento de una enfermedad autoinmunitaria
CO2020010306A2 (es) Compuestos de sulfonimidoilpurinona 7-sustituida y derivados para el tratamiento y profilaxis de cáncer de hígado.
UY39517A (es) Inhibidores de la btk
DOP2022000203A (es) 3-fenoxiazetidin-1-il-pirazinas sustituidas con actividad antagonista gpr52
UY39303A (es) Inhibidores de mutación her2
AR122805A1 (es) Inhibidores de mutación her2
CU20140107A7 (es) Derivados macrocíclicos para el tratamiento de enfermedades
ECSP099644A (es) Derivados de quinolina, composiciones farmacéuticas que los comprenden y el uso de tales en el tratamiento de enfermedades del sistema nervioso central y periférico
ECSP17003149A (es) Compuestos de dihidroisoquinolinona sustituida
CU20140033A7 (es) Derivados de pirrolopirimidina y purina
UY33816A (es) ?nuevas triazolilfenil sulfonamidas como inhibidores de serina/treonina cinasa?.